Search research articles
Contact Us
Filters
Showing results (31-40 of 66) with videos related to
Page
of 7
Sort By:
Cancer Chemotherapy and Pharmacology
|
June 28, 2007
The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity
Lonnie P Swift, Suzanne M Cutts, Abraham Nudelman, et al.
Pest Management Science
|
August 1, 2007
Aryl chain analogues of the biotin vitamers as potential herbicides. Part 3
Tali Ashkenazi, Dalia Pinkert, Ayelet Nudelman, et al.
Cancer Chemotherapy and Pharmacology
|
April 23, 2022
An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells
Oula C Mansour, Abraham Nudelman, Ada Rephaeli, et al.
Journal of Medicinal Chemistry
|
January 1, 2008
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties
Dikla Engel, Abraham Nudelman, Nataly Tarasenko, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
July 26, 2021
Comparison of the tissue distribution and metabolism of AN1284, a potent anti-inflammatory agent, after subcutaneous and oral administration in mice
Michal Weitman, Corina Bejar, Michal Melamed, et al.
Clinical & Experimental Metastasis
|
May 29, 2008
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
Nataly Tarasenko, Abraham Nudelman, Igor Tarasenko, et al.
Molecular Cancer Therapeutics
|
December 24, 2005
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
Michal Entin-Meer, Ada Rephaeli, Xiaodong Yang, et al.
Cancer Chemotherapy and Pharmacology
|
November 22, 2007
Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species
Inesa Levovich, Abraham Nudelman, Gili Berkovitch, et al.
Plos One
|
March 3, 2012
Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor
Nataly Tarasenko, Suzanne M Cutts, Don R Phillips, et al.
Molecular Cancer Therapeutics
|
April 14, 2007
Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate
Suzanne M Cutts, Lonnie P Swift, Vinochani Pillay, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 66) with videos related to
Sort By:
Page
of 7
Cancer Chemotherapy and Pharmacology
|
June 28, 2007
The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity
Lonnie P Swift, Suzanne M Cutts, Abraham Nudelman, et al.
Pest Management Science
|
August 1, 2007
Aryl chain analogues of the biotin vitamers as potential herbicides. Part 3
Tali Ashkenazi, Dalia Pinkert, Ayelet Nudelman, et al.
Cancer Chemotherapy and Pharmacology
|
April 23, 2022
An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells
Oula C Mansour, Abraham Nudelman, Ada Rephaeli, et al.
Journal of Medicinal Chemistry
|
January 1, 2008
Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties
Dikla Engel, Abraham Nudelman, Nataly Tarasenko, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
July 26, 2021
Comparison of the tissue distribution and metabolism of AN1284, a potent anti-inflammatory agent, after subcutaneous and oral administration in mice
Michal Weitman, Corina Bejar, Michal Melamed, et al.
Clinical & Experimental Metastasis
|
May 29, 2008
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
Nataly Tarasenko, Abraham Nudelman, Igor Tarasenko, et al.
Molecular Cancer Therapeutics
|
December 24, 2005
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
Michal Entin-Meer, Ada Rephaeli, Xiaodong Yang, et al.
Cancer Chemotherapy and Pharmacology
|
November 22, 2007
Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species
Inesa Levovich, Abraham Nudelman, Gili Berkovitch, et al.
Plos One
|
March 3, 2012
Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor
Nataly Tarasenko, Suzanne M Cutts, Don R Phillips, et al.
Molecular Cancer Therapeutics
|
April 14, 2007
Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate
Suzanne M Cutts, Lonnie P Swift, Vinochani Pillay, et al.
Page
of 7